Amycretin: the GLP-1/amylin combo in oral and injectable trials

Amylin is a hormone co-released with insulin after meals; it slows gastric emptying, promotes fullness, and quiets glucagon, working through a satiety channel distinct from the incretin system GLP-1 uses. Adding it to GLP-1 is the same additive-satiety logic behind CagriSema and the dual agonists: engage more than one appetite pathway for a deeper effect.

Amycretin's twist is efficiency: one molecule doing both jobs, which simplifies formulation and, crucially, makes an oral version more feasible.

The injectable results matter, but the oral amycretin program is the one reshaping expectations. The current oral option, Rybelsus, trails the injectables and demands a strict empty-stomach ritual. A pill that delivers top-tier weight loss would change the access equation entirely: no needles, easier manufacturing and distribution, and a lower barrier for people who never start injections.

That is why early oral amycretin readouts drew outsized attention. If they hold up through larger trials, an oral drug rivaling the best shots would be a genuine shift, not an incremental one.

Early-phase readouts reported striking weight loss, with some suggesting amycretin could match or exceed current injectable leaders. The honest framing: these are early-phase results in relatively small groups over limited durations, exactly the stage where numbers look their most dramatic and also where they are least settled.

Phase 3 is what converts promising early data into an approvable, fully characterized medicine with a known safety and durability profile. Amycretin is not there yet.

Side effects so far track the class GI pattern (nausea and related effects during escalation), and amylin adds its own nausea contribution, but the full safety profile is not yet characterized, which is precisely what early-stage means.

The market caution is sharp for a drug this early and this hyped: there is no legitimate way to obtain amycretin, and anything sold under the name is unregulated gray-market chemistry with no oversight. An early-phase molecule is the last thing to trust to an unverified source.

Early enough that timelines are speculative. Amycretin has generated headlines on preliminary data, but it still needs the full phase 3 program before any regulatory submission, and results at scale sometimes look different from early promise.

So treat amycretin as the exciting horizon it is, not a near-term option. If you want the future's benefits, the move is unchanged: build the habits that make any of these drugs work (protein, training, honest tracking) on whatever you and your prescriber choose today. DoseLog carries those habits forward to whatever you switch to later.